ProCE Banner Activity

Targeting BCMA in Multiple Myeloma: Evidence-Based Guidance for Current and Near Future Clinical Integration

Slideset Download
Download these slides with the most recent data on BCMA-targeted agents in multiple myeloma, including information on mechanism of action, clinical trial data, and implications for clinical practice.

Released: April 04, 2022

Expiration: April 03, 2023

No longer available for credit.

Share

Faculty

Nina Shah

Nina Shah, MD

Professor of Clinical Medicine
Division of Hematology-Oncology
Department of Medicine
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Pfizer, Inc.

Faculty Disclosure

Primary Author

Nina Shah, MD

Professor of Clinical Medicine
Division of Hematology-Oncology
Department of Medicine
University of California, San Francisco
San Francisco, California

Nina Shah, MD, has disclosed that she has received research funding from Bluebird Bio, Celgene/Bristol-Myers Squibb, Nektar, Poseida, Precision Biosciences, Sutro Biopharma, and Teneobio and has served as a consultant, advisor, and speaker for Amgen, CareDx, CSL Behring, Indapta Therapeutics, GlaxoSmithKline, Karyopharm, Kite, Oncopeptides, and Sanofi.